Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

ElectroCore appoints Desitin to launch gammaCore for the treatment of primary headache across Germany

July 27, 2015 at 12:00 AM EDT
Basking Ridge, New Jersey: ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016. 

Desitin, who are a pan European pharma based in Hamburg, presently focus on treatments in Parkinson’s and epilepsy. Their existing CNS salesforces covering these diseases will also detail gammaCore to those specialist neurologists who also treat headache. 

GammaCore is well known in Germany as many of the headache centres across the country took part in the successful clinical trial program. 

CEO of electroCore JP Errico commented, “We are very pleased to partner with Desitin. Their understanding of the CNS marketplace in Germany will bring great benefits to patients. It was very important to us to have a pharmaceutical partner as they better understand the business model which is most appropriate for bioelectronics.” 

CEO of Desitin commented, “We believe that with our expertise in the CNS area and with a specialist salesforce we will be able to explain the significant therapeutic benefits of gammaCore firstly to the neurologists and through them to the patients. Compared to most treatments in this area gammaCore has virtually no side effects and has proven to be very effective in both preventing and treating cluster headache and migraine. We are really delighted to be working with electroCore to bring this treatment to patients across Germany.” 

Desitin background 

DESITIN ARZNEIMITTEL GMBH which was founded in 1919 and is based in Hamburg is a medium sized pharma focused on the development and sales of medication for illnesses of the central nervous system (CNS) particularly the treatment of epilepsy, Morbus Parkinson, dystonia and now primary headache. 

The company activities are focused on Europe with subsidiaries in 11 countries and distributors in 12 others.